BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...

Stock analysts at BMO Capital Markets started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a ...

Dyne Therapeutics (NASDAQ:DYN) traded higher in the premarket on Wednesday after BMO Capital Markets launched its coverage with an Outperform recommendation and a $50 per share target, citing the ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 ...

BMO Capital analyst Kostas Biliouris initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Dyne Therapeutics (NasdaqGS:DYN) with a Outperform recommendation. As of March 4, 2025, the average one-year price target ...

Chardan Capital reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a report issued on ...

When Might Dyne Therapeutics Run Out Of Money? A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Dyne Therapeutics last reported its December 2024 balance ...

WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...

BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price ...